Trends Shaping the Growth in US Pharma Over the Next Four Years

The pharmaceutical industry shows remarkable investment growth despite market challenges. Cell and gene therapy startups alone secured USD 26 billion in funding. Total investment in CGTs reached $15.2 billion in 2025 – a 30% jump over 2023.

These impressive funding numbers emerge at a crucial time. Biopharma’s average total shareholder return was 0% from 2021 to 2025, while the S&P 500 achieved 16%. A looming patent cliff puts some $275 billion in revenue at risk from loss of exclusivity across the top 15 companies.

Several factors drive these pharma industry trends. The FDA had approved 46 cell and gene therapy products by mid-2025, which shows strong regulatory support for breakthroughs. On top of that, AI adoption grows faster, and experts project the AI pharma market to expand from US $1.9 billion in 2025 to more than US $16 billion by 2034.

The pharmaceutical sector continues to evolve significantly. Venture capital funding in biotech grew year-over-year to USD 21.4 billion in 2025. Demographic changes create new market opportunities – by 2030, one in six people globally will be aged 60 or older. This aging population increases the need for chronic care, neurology, and specialty medicines.

Our complete pharmaceutical industry trends analysis gets into the key forces that reshape the US pharma digital world over the next four years. We back our findings with thorough market research reports and data.

AI and Machine Learning in Pharma R&D

_{Image Source: Nature}

AI is changing the pharmaceutical world fast. The global AI in pharma market will grow from USD 4 billion in 2023 to USD 25.70 billion by 2030. This growth shows how medications are now found, developed, and marketed differently. Let’s get into how these technologies work across the pharmaceutical value chain.

AI and Machine Learning in Pharma R&D: Key Applications

AI integration in pharmaceutical R&D tackles industry challenges through several key applications:

Target Identification and Verification: AI systems analyze huge biological datasets to find new drug targets faster than ever before. Machine learning models look through biomedical data—including genomics, electronic health records, and scientific literature. They find connections between genes, proteins, and diseases that humans might miss. These systems cut target identification time from months to weeks.

Molecule Design and Optimization: AI models like GENTRL and ChemBERTa create new molecular structures based on desired properties before any physical synthesis. These models treat molecular design as a language problem. They can simulate how small molecules, peptides, antibodies, or RNA therapies interact with target proteins.

Property Prediction: Smart algorithms predict a molecule’s toxicity, efficacy, and pharmacokinetics before synthesis. Research shows these simplified processes have cut the time to bring a new molecule to preclinical stage by 40% and costs by 30%.

Clinical Trial Optimization: AI simplifies trial design and execution through:

• Patient stratification and recruitment matching

• Predictive outcome modeling

• Digital twin creation for simulation

• Real-time monitoring and protocol adjustments

Lykke Hinsch Gylvin of Boehringer Ingelheim says, “These tools help us to accelerate speed while minimizing the number of patients on the placebo control arms, which is a win–win for us and the industry”.

AI and Machine Learning in Pharma R&D: Business Impact

AI creates measurable business value in pharmaceutical R&D:

Faster Development: AI-designed drugs show an 80-90% success rate in Phase I clinical trials. Traditional medications achieve only 40-65%. Development time could drop from 10-15 years to 3-6 years.

Lower Costs: AI helps pick better compounds and needs fewer experiments. This cuts drug development costs by up to 70%. A single drug typically costs over USD 2 billion to market with a 90% failure rate for new molecular entities. These savings make a big difference.

Value Creation: A complete analysis of over 200 AI use cases with 25 experts shows pharmaceutical companies could gain USD 254 billion in operating profits worldwide by 2030 through AI industrialization. The US share alone could be USD 155 billion.

Department Benefits: R&D makes up 26% of AI’s potential value, with commercial applications at 24%. AI boosts efficiency and revenues by creating new medicines and market interactions.

Market Growth: The AI pharmaceutical market could reach USD 16.49 billion by 2034, growing at 27% CAGR from 2025. Oncology leads with 21% market share in 2024.

AI and Machine Learning in Pharma R&D: Ground Examples

Leading companies show how AI works in pharmaceutical R&D:

Exscientia’s Breakthrough: Exscientia and Sumitomo Dainippon Pharma created history with the first AI-designed molecule for obsessive-compulsive disorder in Phase 1 trials. Their Centaur Chemist platform makes molecules faster than traditional methods.

Insilico Medicine’s Speed: Insilico Medicine found a new drug target and designed a molecule for pulmonary fibrosis. It reached Phase II trials in just 18 months. Their Pharma.AI platform works like an operating system for drug discovery. It connects target identification, molecule generation, and clinical trial prediction.

Johnson & Johnson’s Clinical Applications: J&J uses algorithms to review diagnostic images and find suitable patients for new treatments. They also use deep-learning algorithms to check tissue samples from bladder cancer patients for trial eligibility. Ashita Batavia from J&J explains: “[To a] digital pathology image we could apply an algorithm that we built and validated to predict the presence or absence of a qualifying mutation for a trial, which pathologists are unable to do”.

GSK’s Data-First Approach: GSK built a strong global team called Onyx for large-scale data engineering. Kim Branson of GSK says, “The big thing for us was generating data with the explicit purpose of building models, because we believe that’s a source of advantage”.

Genentech’s Lab-in-the-Loop Model: Genentech puts AI directly into experimental workflows through a ‘lab-in-the-loop’ model. Marioni from Genentech explains, “We start with the model, receive a prediction, verify it, and then improve the model. It’s a virtuous circle… you keep doing that until the model can generate good predictions that can complement and guide the next experiments that are being done”.

The FDA sees AI’s growing importance in drug development. They report more drug applications using AI components in the last few years. These technologies will reshape the pharmaceutical industry’s future.

Gene Editing and Precision Genomics

_{Image Source: Frontiers}

Precision genomic technologies are transforming the pharmaceutical world. The global precision genomic testing market will grow from USD 15.49 billion in 2024 to USD 35.20 billion by 2030. This remarkable growth shows a 14.8% CAGR from 2025 to 2030, making it one of the most promising areas in pharma industry trends.

Gene Editing and Precision Genomics: Key Technologies

Gene editing technologies now provide sophisticated tools that address genetic disorders at their source:

CRISPR-Cas9 Systems: Scientists found that there was a bacterial defense mechanism in 2012, and CRISPR has become the leading gene editing platform. CRISPR uses RNA-DNA interactions instead of protein-DNA interactions, which makes it more available and versatile than earlier technologies. About 45.4% of commercial researchers and 48.5% of non-commercial researchers now use CRISPR as their main modification method.

Base Editors: These innovative tools can make precise nucleotide conversions without causing double-stranded DNA breaks. Base editors combine catalytically modified Cas proteins with deaminases to correct point mutations that cause most disease-associated genetic variations. This approach showed it can correct about 30% of known disease-causing mutations.

Prime Editors: Scientists developed prime editors in 2019, and they work like a “search-and-replace” tool for DNA. Prime editors can insert, delete, or swap entire sequences without donor DNA, which goes beyond traditional CRISPR or base editors’ capabilities. These systems have successfully treated genetic disorders like sickle cell disease and phenylketonuria in preclinical studies.

Delivery Systems: Gene editing’s therapeutic application uses three main delivery methods: ribonucleoprotein complex (RNP), non-viral delivery, and viral vectors like AAV or lentivirus. These systems enable both ex vivo modification and in vivo approaches.

Gene Editing and Precision Genomics: Clinical Progress

Clinical adoption of gene editing technologies has made breakthrough advances:

Historic Personalized Treatment: Children’s Hospital of Philadelphia and Penn Medicine’s team achieved a groundbreaking success. They treated a child with a rare genetic disorder using a customized CRISPR gene editing therapy. The team created and produced a base editing therapy using lipid nanoparticles to correct the patient’s specific variant of CPS1. This individual-specific approach marks a radical alteration from pharmaceutical development’s traditional “one-size-fits-all” model.

First Approved Gene Editing Therapies: Vertex Pharmaceuticals and CRISPR Therapeutics got UK approval for the first gene-edited product in 2023. They developed an ex vivo gene-edited stem cell therapy for sickle cell disease and transfusion-dependent beta thalassemia. The FDA then approved Casgevy (exagamglogene autotemce), which uses CRISPR-Cas9 to reactivate dormant hemoglobin genes in sickle cell disease patients.

Expanding Clinical Pipeline: Gene editing-based therapies have 18 ongoing clinical trials worldwide. The FDA has also approved the first clinical trial of prime-editing therapy for chronic granulomatous disease (CGD), which pushes gene editing’s therapeutic boundaries further.

Gene Editing and Precision Genomics: Future Outlook

Pharmaceutical industry trends suggest continued growth in precision genomics:

Market Growth Trajectory: The broader genomics market will grow from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a 12.6% CAGR. The gene editing therapeutics market will expand from USD 11 million in 2024 to USD 1 billion by 2029—showing an incredible 147% CAGR.

Oncology and Neurological Focus: Oncology leads the precision genomic testing market with a 31.50% share in 2024. The neurological disorders segment will grow fastest at 15.57% CAGR from 2025 to 2030. This growth comes from better identification of genetic mutations linked to Alzheimer’s, Parkinson’s, and epilepsy.

Integration with AI: Precision genomics and artificial intelligence are creating powerful new capabilities together. AI systems can spot patterns in large genomic datasets, which leads to more precise diagnoses, novel therapeutic targets, and individual-specific treatment plans. Machine learning algorithms spot complex patterns in genomic data that traditional bioinformatics methods might miss.

Democratization of Treatment: Gene editing technologies will expand beyond rare diseases to address common conditions. Jon Moore, chief scientific officer at Horizon Discovery, explains: “The targets we’re finding with CRISPR-Cas9 are going to guide the drugs coming out in the 2030s”. This development will keep transforming the pharmaceutical industry toward more targeted, effective therapeutic approaches.

Advanced Modalities and Therapies

_{Image Source: Boston Consulting Group}

Advanced therapy medicinal products (ATMPs) are revolutionizing treatment approaches across the pharmaceutical industry. These innovations go well beyond traditional small molecules and simple biologics. This transformation has created new possibilities for treating conditions that previously had limited or no effective treatments.

Advanced Modalities and Therapies: What’s Emerging

Several groundbreaking approaches now target disease mechanisms in innovative ways:

Cell Therapies: These treatments use cells with modified biological characteristics or functions different from their intended purpose. Chimeric antigen receptor T-cell (CAR-T) pipelines show rapid growth through 2025, while companies pursue in vivo CAR-T approaches to overcome logistical challenges. Ryoncil (Mesoblast) made history as the first mesenchymal stromal therapy to get FDA approval in 2025 for pediatric steroid-refractory acute graft-versus-host disease.

Gene Therapies: Genetic material transfer to patients offers potential cures for inherited disorders and certain cancers. The FDA temporarily paused Elevidys (Sarepta) shipments due to safety concerns in 2025, highlighting increased regulatory scrutiny.

Antibody-Based Innovations: Modern antibodies surpass conventional approaches through formats like antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered antibodies. ADCs merge antibody specificity with cytotoxic drug potency to reduce systemic toxicity. The ADC pipeline expanded by a lot with 284 oncology trials in 2024—nearly 100 more than 2023—making it the fastest-growing modality in solid tumors.

Nucleic Acid Therapies: This category includes antisense oligonucleotides and RNA-based treatments. The projected revenue jumped 65% year-over-year, driven by newly approved antisense oligonucleotides such as Rytelo (Geron), Izervay (Astellas), and Tryngolza (Ionis).

These advanced modalities feature novel mechanisms of action that target the genome, transcriptome, or proteome differently than traditional drugs. Their engineered nucleic acids or cellular components achieve higher specificity and often allow personalization based on individual genetic or molecular profiles.

Advanced Modalities and Therapies: Market Adoption

Advanced therapeutics show substantial growth potential across all modalities. The projected new-modality pipeline value reached USD 197 billion in 2025, rising 17% from 2024, outpacing conventional modalities by a lot.

Market growth for key advanced therapy segments through 2030 includes:

• Gene therapy market: USD 20-25 billion

• RNA therapeutics market: USD 15-20 billion

• Cell therapy market: USD 30-40 billion

• Protein degradation and gene editing combined: USD 10-15 billion

ADCs demonstrated remarkable growth with a 40% increase in expected pipeline value last year and a 22% CAGR in the last five years. Bispecific antibodies, targeting two antigens simultaneously, saw a 50% rise in forecasted pipeline revenue.

Major companies have restructured their R&D divisions to prioritize more than 2,000 active programs in advanced modalities. The top 20 biopharma companies invested USD 170 billion in new-modality deals from 2023 through 2025, with antibody technologies receiving over half the investment.

Chinese companies have emerged as significant players with more than 4,000 clinical-stage new-modality drugs in their pipelines, second only to the US. To cite an instance, China now originates more than 30% of assets in global antibody and cell therapy pipelines.

Advanced Modalities and Therapies: Regulatory Support

Global regulatory agencies have adapted their frameworks to support advanced therapies:

The US FDA’s Office of Therapeutic Products provides regulatory oversight for advanced therapies. This office aids sponsor interactions through informal and formal meetings, including INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs) for early development feedback.

The FDA provides expedited programs for advanced therapies, including Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation. These programs offer intensive guidance and increased interactions for products treating serious conditions.

The European Medicines Agency has created specific GMP guidelines for ATMPs that adapt requirements to their unique characteristics while promoting a risk-based approach to manufacturing and testing. Developers of ATMPs can get fee reductions to encourage research and development.

Regulators in Japan, Canada, and other regions have created specialized frameworks for these products. Canada’s regulatory approach allows a flexible, risk-based strategy through its Advanced Therapeutic Products framework.

Major regulatory bodies have developed frameworks that bridge innovation and patient access, which speeds up the growth of this transformative pharmaceutical sector.

Smart Manufacturing and Automation

_{Image Source: IoT Analytics}

As investment shifts toward advanced therapies and new manufacturing models, many organizations are rethinking how their facilities, automation, and data platforms support long-term returns.

Avid helps biopharma teams evaluate modernization opportunities across GMP manufacturing, utilities, and digital infrastructure — and define realistic, low-risk paths forward.

If that would be useful, let’s start with a conversation! https://avidsolutionsinc.com/contact-avid/